Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:06 PM
Ignite Modification Date:
2025-12-24 @ 10:06 PM
NCT ID:
NCT00000735
Eligibility Criteria:
Inclusion Criteria
Hemophiliacs are included. Patients must have:
* Consistently positive serum HIV p24 antigen (= or \> 70 pg/ml) defined by the Abbott HIV antigen test. This demonstration must be seen on two occasions, each separated by at least 72 hours, the last of which must be within 2 weeks of starting therapy.
* Positive HIV antibody test.
Prior Medication:
Allowed:
* Acyclovir for short course (7 days).
* Ketoconazole for short course (7 days).
* Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis.
* Trimethoprim / sulfamethoxazole for PCP prophylaxis.
Exclusion Criteria
Co-existing Condition:
Patients with AIDS encephalopathy as a sole indicator are excluded.
Patients with AIDS encephalopathy as a sole indicator are excluded.
Prior Medication:
Excluded:
* Other experimental medication.
* Antineoplastic therapy.
* Amphotericin B.
* Ganciclovir.
* Excluded within 14 days of study entry:
* Biologic modifiers.
* Corticosteroids.
* Excluded within 30 days of study entry:
* Other antiretroviral agents.
* Excluded within 60 days of study entry:
* Ribavirin.
Active drug or alcohol abuse.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
12 Years
Study:
NCT00000735
Study Brief:
Protocol Section:
NCT00000735